Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery - Reuters
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery Reuters
The pharmaceutical industry is under increasing pressure to accelerate drug development timelines and reduce costs, converging with the rapid advancements and commercial availability of sophisticated AI models like Claude.
This move by a major pharmaceutical company demonstrates the growing practical application of advanced AI in scientific discovery, potentially transforming R&D across industries.
The adoption of large language models like Claude by Bristol Myers Squibb indicates a significant shift in how drug discovery processes will be augmented, leading to faster research cycles and potentially more efficient development of therapeutics.
- · Anthropic
- · Bristol Myers Squibb
- · AI Software Providers
- · Pharmaceutical R&D
- · Traditional R&D methodologies
- · Biotech companies without AI integration
Bristol Myers Squibb gains a competitive edge in drug discovery through enhanced efficiency.
Increased competition among pharmaceutical companies to integrate similar advanced AI, driving wider adoption and innovation in AI-powered R&D.
The development of entirely new drug classes and therapies, previously intractable, becomes feasible due to AI's enhanced predictive capabilities and data analysis.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Reuters — Technology (Google News)